Jasper Therapeutics, Inc. - Class A Common Stock — Quarterly Cash Flow (NASDAQ:JSPR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 57.6 M46.47 M57.47 M35.78 M21.18 M11.8 M Total liabilities 15.35 M22.96 M45.9 M31.63 M17.78 M10.39 M Total equity 42.24 M23.5 M11.57 M4.15 M3.4 M1.41 M Total liabilities & shareholders' equities 57.6 M46.47 M57.47 M35.78 M21.18 M11.8 M Total debt —————— Net debt ——————

News

Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer

AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

Rodman & Renshaw initiates Jasper Therapeutics stock with Buy rating

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow (NASDAQ:JSPR) 2026-01-11

Jasper Therapeutics stock rating reiterated at Market Outperform by Citizens

Jasper reports positive data from briquilimab trials in chronic urticaria

Jasper Therapeutics stock rises after leadership changes

Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data - Slideshow (NASDAQ:JSPR) 2025-12-04